logo
ADVM_logo
Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is projected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California. End of study, two-year results across all four cohorts will be presented for the first time

By Adverum Biotechnologies, Inc.
Published - Oct 27, 2022, 04:06 PM ET
Last Updated - Jul 19, 2024, 04:43 AM EDT

REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California. End of study, two-year results across all four cohorts will be presented for the first time.

Oral Presentation Title: ADVM-022 Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: End of Study Results from the 2-Year OPTIC Trial
Session: Age-Related Macular Degeneration II
Date & Time: November 4, 2022, 9:08 AM – 9:14 AM PST
Presenter: Carl Regillo, M.D., F.A.C.S., chief of retina services at Wills Eye Hospital

Adverum intends to issue a press release concurrent with the presentation and to post the data presented on the Publications page in the Pipeline section of the company’s website.

About Wet Age-Related Macular Degeneration

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024